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OBJECTIVES: Health Technology Assessment groups suggest
that registries designed for the purpose of collecting patient data
on resource use and outcomes are a relevant supplement to data
collected in randomized controlled clinical trials because they
reﬂect a routine clinical care setting and enable considered treat-
ment decisions and healthcare resource allocation to be made
(http://www.nice.org). The Electronic Schizophrenia Treatment
Adherence Registry (e–STAR) is a non-interventional, interna-
tional registry designed to evaluate medication usage and long-
term clinical outcomes in patients with schizophrenia or
schizoaffective disorder undergoing a change in antipsychotic
medication in a naturalistic setting. METHODS: In- or out-
patients who start a new antipsychotic medication during the
course of their routine clinical management are eligible for enrol-
ment in the e–STAR project. Data are collected through an inno-
vative Electronic Data Capture system and transmitted to the
registry at baseline—the time of switch to the new medication—
and every 3 months for the following 24 months. Data are also
collected retrospectively for the 12 months preceding baseline. A
secure website is used, which anonymises data and conducts
automated data quality checks before being transmitted to the
registry. Patient data on demographics, treatment and hospitali-
sation history, and clinical outcomes are collected. RESULTS:
Changes in clinical and other outcome measures following a
switch to the new medication will enable clinicians—and other
decision makers—to evaluate the effectiveness and utility of the
treatment switch in a routine clinical care setting by identifying
optimal outcome patterns in deﬁned cohorts of patients. CON-
CLUSION: To date, 6 countries are participating in the e–STAR
project, which aims to enroll at least 5000 patients. This paper
decribes the logistics of the project.
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OBJECTIVES: To estimate the cost-effectiveness of Risperdal
Consta versus a conventional depot and an oral atypical over a
5-year period in Portugal. METHODS: A discrete-event model
was developed comparing three scenarios. In scenario-1, patients
start on haloperidol depot and may be switched to olanzapine
followed by oral risperidone. In scenario-2 patients start on
Risperdal Consta and may be switched to olanzapine followed
by haloperidol depot. In scenario-3, patients start on oral risperi-
done instead of Risperdal Consta. The model simulates individ-
ual patient-histories accounting for age, gender, type, severity of
disease, potential to present risk and side-effects. Based on these
patient characteristics, the model simulates visits, psychotic-
episodes, symptom-score, degree of disorganisation, treatment,
compliance, risk and location. Outcomes are expressed in terms
of number and duration of psychotic episodes, symptoms-score
and costs (psychiatrist visits, medication and location) informa-
tion was derived from literature and an expert panel. RESULTS:
Over a 5-year time-horizon and per patient, starting with
Risperdal Consta was estimated to avoid 0.44 and 0.59 relapses
and to save 3603€ and 4682€ compared to a conventional depot
(scenario-1) and to an oral atypical (scenario-3) respectively. 
In subgroup analysis of only high-risk non-compliant patients
Risperdal Consta was estimated to avoid 0.51 and 0.71 relapses
and to save 5700€ and 10,500€. In the subpopulation with co-
morbid substance abuse, Risperdal Consta was estimated to save
10,300€ and 17,500€ and to avoid 0.33 and 0.50 relapses per
patient respectively. Sensitivity analyses showed that the results
are robust and that they are mainly related to estimates about
location costs, probability to present risk and the effects of atyp-
ical and conventional formulations on the symptom-score.
CONCLUSIONS: Based on the model parameters, Risperdal
Consta combines additional effectiveness with cost savings in
patients with schizophrenia, and should therefore be preferred
as treatment over conventional depots and oral atypical 
formulations.
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OBJECTIVES: Comparing the cost-effectiveness of escitalopram
with venlafaxine and generic citalopram and in the ﬁrst-line
treatment of Major Depressive Disorder (MDD) in the UK (UK).
METHODS: A 2-path decision analytic model with a 6-month
horizon was adapted to the UK setting using local clinical guide-
lines and data. All patients (aged greater than or equal to 18
years) started at the primary care path and were referred to spe-
cialist care in the secondary care path in case of insufﬁcient
response. Model inputs included drug-speciﬁc probabilities
derived from a meta-analysis, clinical trials, GPRD database,
published literature, and expert opinion. Unit costs (in 2003
GBP) were taken from the literature. Main outcome measures
were success [i.e., remission deﬁned as Montgomery-Åsberg
Depression Rating Scale (MADRS) score less than or equal to
12] and costs of treatment. The analysis was performed from the
National Health Service (NHS) and societal perspectives. The
Human Capital approach was used to estimate the societal costs
of lost productivity. RESULTS: From both perspectives, treat-
ment with escitalopram yielded lower expected cost and greater
success of treatment compared with generic citalopram. The
expected success rate for escitalopram was higher (63.5%) com-
pared with generic citalopram (58.2%). From the NHS perspec-
tive, the expected cost per successfully treated patient was £201
lower for escitalopram (£732) compared with generic citalopram
(£933). From the societal perspective, the difference was £884
between expected costs of £3635 and £4519. Escitalopram
demonstrated similar treatment success to that of venlafaxine at
lower costs (£53 and £61, for NHS and societal perspectives,
respectively). Multivariate sensitivity analyses demonstrated the
robustness of the model and that escitalopram remained the
dominant treatment option even at an acquisition cost of £0 for
generic citalopram. CONCLUSIONS: Escitalopram is a cost-
effective alternative compared to generic citalopram and ven-
lafaxine in the ﬁrst-line treatment of MDD in the UK.
